Gross Profit Comparison: Incyte Corporation and Ligand Pharmaceuticals Incorporated Trends

Biotech Giants: Incyte vs. Ligand's Profit Trends

__timestampIncyte CorporationLigand Pharmaceuticals Incorporated
Wednesday, January 1, 201450849100055402000
Thursday, January 1, 201572677900066107000
Friday, January 1, 20161047532000103402000
Sunday, January 1, 20171456737000135736000
Monday, January 1, 20181787760000245116000
Tuesday, January 1, 20192044510000108935000
Wednesday, January 1, 20202535374000156000000
Friday, January 1, 20212835276000214957000
Saturday, January 1, 20223187638000143418000
Sunday, January 1, 2023344064900096265000
Monday, January 1, 20243929149000
Loading chart...

Infusing magic into the data realm

A Decade of Growth: Incyte vs. Ligand Pharmaceuticals

In the ever-evolving landscape of biotechnology, Incyte Corporation and Ligand Pharmaceuticals Incorporated have showcased distinct trajectories over the past decade. From 2014 to 2023, Incyte's gross profit surged by an impressive 577%, reflecting its robust growth strategy and market adaptability. In contrast, Ligand Pharmaceuticals experienced a more modest increase of 74% during the same period, highlighting its steady yet slower growth pace.

Key Insights

  • Incyte's Dominance: By 2023, Incyte's gross profit reached approximately 3.44 billion, a testament to its strategic investments and innovative pipeline.
  • Ligand's Steady Climb: Despite a smaller scale, Ligand's gross profit peaked at around 245 million in 2018, before stabilizing.

This comparison underscores the dynamic nature of the biotech sector, where strategic foresight and innovation drive financial success.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025